NVNadezhda G. Veselovskaya

Nadezhda G. Veselovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadezhda G. Veselovskaya has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Restrictive cardiomyopathy: difficulties in diagnosis and management. A case report

    by N. G. Veselovskaya, A. V. Ott, G. A. Chumakova, E. V. Trubina, Yu. G. Motin, E. S. Frolova, Н. Г Веселовская, А. Н. Отт, Г. А. Чумакова, Е. В. Трубина, et al.

    Intr oduction . Despite recent advances in the diagnosis and treatment of various cardiomyopathies (CMP), the diagnosis of restrictive cardiomyopathy (RCM) remains the most challenging due to the heterogeneity of etiologic factors and the lack of timely interpretation of echocardiographic criteria for myocardial restriction. The association of RCM with the most common cardiovascular diseases further complicates its diagnosis. At the same time, the prognosis for patients with RCM, especially those with a genetic basis, is significantly worse than for other forms of cardiomyopathy. Brief description. This article presents a case of a 47-year-old female patient diagnosed with myocardial infarction complicated by heart failure (HF) refractory to cardiotropic therapy. Delayed assessment of cardiac anatomical parameters (atrial dilation with small ventricular sizes), the type of left ventricular diastolic dysfunction, and the characteristics of myocardial longitudinal strain abnormalities led to a late RCM diagnosis, imitating HF secondary to myocardial infarction. Identification of the genetic disease nature (a mutation in the genes encoding sarcomeric proteins) facilitated the selection of a curative treatment option — heart transplantation. Discussion . This clinical example highlights the need for a thorough approach to diagnosing various cardiomyopathy types using primary and secondary echocardiographic criteria, and, if necessary, genetic testing, especially in cases of refractory heart failure despite ongoing cardiotropic therapy.

  • Associated pulmonary arterial hypertension: difficulties in diagnosis and management. A case report

    by L. V. Barinova, E. S. Frolova, N. G. Veselovskaya

    Introduction. Despite recent advances in the diagnosis and treatment of pulmonary arterial hypertension (PAH), including those associated with systemic connective tissue diseases (CTDs), late diagnosis persists in clinical practice. Newly diagnosed patients with PAH associated with CTDs experience significant functional and hemodynamic impairment and a high mortality risk. The prognosis for this category of patients is significantly worse than for other PAH types. PAH is a rare but severe complication of systemic lupus erythematosus, the exact etiopathogenesis of which remains unknown. Brief description . This article presents a case of a 54-year-old female patient diagnosed with coronary artery disease, coronary artery stenting, and a primary complaint of shortness of breath, which, in fact, masks the manifestation of CTDs. Echocardiography-­based diagnosis of pulmonary hypertension was long interpreted as a manifestation of heart failure, despite the absence of left heart remodeling. Further examination confirmed systemic lupus erythematosus and associated pulmonary arterial hypertension (PAH), followed by the initiation of PAH-specific therapy with improved dynamics of the main risk criteria. Discussion. This case emphasizes the need for a thorough collection of complaints and medical history, not only related to obvious cardiovascular symptoms but also those of other systems and organs. In addition, a more detailed assessment of echocardiographic parameters with differential diagnosis of common causes of dyspnea from less common ones should be performed.

  • Open Access

    Predictors of chronic heart failure in patients with hypertension and pre–heart failure: a cohort study

    by Venera V. Kirillova, Svetlana D. Mayanskaya, Nadezhda G. Veselovskaya

    BACKGROUND: Identifying predictors of chronic heart failure is an essential preventive step in patients with pre–heart failure. AIM: This study aimed to identify predictors of chronic heart failure development in outpatients with hypertension and pre–heart failure. METHODS: A single-center study included 356 outpatients with hypertension and pre–heart failure. The mean age was 62.65 ± 10.59 years; 128 (36%) participants were men. The patients received drug therapy for hypertension, with treatment adjustment after 1 and 3 months and subsequently annually for 3 years. Later on, outcomes defined as the development of chronic heart failure were evaluated. Multiple binary logistic regression analysis was used to identify predictors of chronic heart failure onset. RESULTS: Over a 3-year period (2022–2025), chronic heart failure with preserved ejection fraction developed in 8.7% of patients with hypertension and pre–heart failure. Analysis of risk factors showed that patients who developed chronic heart failure were older (66.37 ± 9.55 years; p 0.001), had a longer duration of hypertension (17.85 ± 10.43 years; p 0.001), higher body mass index (29.41 ± 4.85 kg/m2; p = 0.002), and a lower glomerular filtration rate (73.23 ± 18.19 mL/min/1.73 m2; p 0.001). In this group, paroxysmal (p 0.001) and persistent atrial fibrillation (p 0.001), as well as type 2 diabetes mellitus (p 0.001), were observed more frequently. In these patients, more pronounced structural and functional cardiac changes were already present at enrollment into the study, namely, indexed left atrial volume (47.93 ± 14.85 vs 33.68 ± 5.57 mL/m2; p 0.001), indexed myocardial mass (104.18 ± 29.34 vs 92.55 ± 19.36 g/m2; p = 0.045), maximum pulmonary vein diameter (21.23 ± 2.24 vs 17.34 ± 1.64 mm; p 0.001), and minimum pulmonary vein diameter (11.09 ± 2.42 vs 7.36 ± 1.53 mm; p 0.001). The predictors associated with the onset of chronic heart failure after 3 years in patients with hypertension included maximum pulmonary vein diameter, left atrial volume, age, body mass index, and the presence of atrial fibrillation. CONCLUSION: Within 3 years, chronic heart failure with preserved ejection fraction developed in 8.7% of patients with pre–heart failure. Predictors of its development in patients with hypertension included maximum pulmonary vein diameter, left atrial volume, age, body mass index, and the presence of atrial fibrillation.

  • Open Access

    Microvesicles and their role in cardiovascular pathology

    by N. S. Gorbacheva, N. G. Veselovskaya, A. P. Momot, G. A. Chumakova, P. A. Gorbacheva

    In recent years, there has been a tendency to increase the number of acute myocardial infarctions (AMI) in young people. The search and study of risk factors (FR), pathogenetic mechanisms of cardiovascular complications (CVD) and methods of targeted exposure continues.One of the mechanisms of MTR is the pathology of the hemostasis system-. vascular-platelet (microvesicles), coagulation hemostasis (thrombin, tissue factor\tissue factor inhibitor) and fibrinolysis systems (coagulation factor II and XIII), an imbalance of which can lead to vascular catastrophes. In recent decades, microvesicles of various origins have been studied with precision.Microvesicles are found in the blood normally, but in vascular catastrophes their number increases significantly in the first hours of developing pathology. To assess the quantity and quality of microvesicles may allow timely initiation of therapy, which will lead to a decrease in the focus of ischemia and the development of various early and long-term complications.Normally, microvesicles act as protectors, and their increase occurs in pathological processes. An increase in the concentration of microvesicles of various natures (leukocyte, platelet, erythrocyte) has been studied in oncology, obstetrics and gynecology, as well as in cardiovascular pathology. The determination of microvesicles in the blood can allow stratification of patients into high-risk groups, will allow early therapy to begin.The study of the hemostasis system, especially individual components (microvesicles), allows us to gain new knowledge about the mechanisms of AMI development in the absence of traditional risk factors, to identify prognostically significant biological markers, as well as their concentration, allowing us to predict the risk of coronary events and complications in young patients.

  • Open Access

    PREDICTORS OF HOSPITAL COMPLICATIONS FOLLOWING AORTIC VALVE PROSTHESIS IN OBESE PATIENTS

    by Nadezhda G. Veselovskaya, Anna V. Ott, Ekaterina S. Frolova, Vlada E. Sapiyan, Anastasia V. Maslova

    Obesity is a global epidemic of the 21st century. Adipose tissue has pro-inflammatory and pro-fibrotic activity and leads to the development of endothelial dysfunction, resulting in cardiovascular disease (CVD). According to large international studies, obesity is a common comorbid condition in patients with aortic stenosis (AS). Surgical aortic valve replacement (SAVR) remains the «gold» standard for the treatment of patients with severe AS; however, obesity patients represent a group at increased risk of postoperative hospital postoperative complications. Therefore, an important area in modern cardiology is the study of risk factors (RF) for complications after SAVR in patients with obesity, with the development of an individualized preoperative preparation.

  • Open Access

    COVID-19 and post-disease features in patients with obesity

    by Ekaterina S. Frolova, Pavel P. Veselovsky, Galina A. Chumakova, Nadezhda G. Veselovskaya, Anna V. Ott

    The COVID-19 pandemic has affected the global population, causing significant economic effect, material damage, and irreparable human losses. Many countries were forced to promptly reorganize their healthcare system in order to save patients with COVID-19. The pathogenesis and specifics of the disease are not completely understood, but one pattern is particularly clear: COVID-19 tends to be more severe in people with obesity. Fatty tissue is known to support chronic low-grade inflammation and has its own endocrine activity. Over time, it became obvious that some patients still have consequences following the acute phase of COVID-19, which in some cases lead to irreversible changes in the body and reduced quality of life. This condition was called post-COVID syndrome. In this article, we review the long-term effects of COVID-19 on different body systems. We focused on pathogenic infection mechanisms and features of post-COVID syndrome in people with obesity.

  • Open Access

    Propensity score matching analysis of the aortiv valve replacement with the xenopericardial semi-framed prosthesis “T-Ara” and the framed xenopericardial prosthesis “UniLine”. Short-term results

    by A. V. Evtushenko, A. N. Stasev, S. G. Kokorin, I. N. Sizova, D. I. Lebedev, M. K. Duvanov, A. V. Maximov, N. G. Veselovskaya, K. Yu. Scherbakov, L. S. Barbarash

    Highlights. It is the first pseudorandomized comparative study of xenopericardial frame and half-frame bioprostheses treated with diepoxin in the aortic position use and its direct results.Aim. A comparative assessment using the Propensity Score Matching method of the in-hospital clinical and hemodynamic results of the semi-framed epoxy-treated xenopericardial prosthesis “T-ara” and the framed epoxy-treated xenopericardial prosthesis “UniLine” (“NeoKor”, Kemerovo, Russia) for isolated aortic valve replacement implantation.Methods. 33 recipients of the “UniLine” prosthesis were selected by Propensity Score Matching method in a ratio of 1:1 to 33 observations from the “T-ara” group according to the compliance criteria: gender, age, body surface area, end-diastolic volume of the left ventricle (LV) and the pre-operative presence/absence of the aortic regurgitation.Results. Hospital mortality in the “T-ara” and “UniLine” groups was 3.03 (n = 1) and 6.06% (n = 2), respectively, p = 0.920. Non-fatal complications in the “T-ara” and “UniLine” groups was 7 (21.2%) and 18 (54.6%), p = 0.163. The incidence of postoperative heart failure and arrhythmias was higher in “UniLine” recipients (p = 0.001). The average stay in the intensive care unit was longer in the “UniLine” group than in the “T-ara” group, p = 0.05. Postoperative end-systolic and end-diastolic dimensions and volumes (and the corresponding indexes) of the LV, as well as the myocardial mass and its index in both groups had no statistically significant changes in relation to preoperative data. The comparative assessment of left ventricular remodeling parameters depending on the prosthetic size revealed no significant differences. The average pressure gradient in the “T-ara» and “UniLine” group of size 21mm was 12.2±7.4 and 12.2±5.0 mm Hg. (p>0.050). The average pressure gradient in the group “T-ara” and “UniLine” size 23–25 mm was 10.2±4.1 and 9.9±0.3 mm Hg, p>0.050. The regression degree of LV myocardial mass index in the groups did not have significant differences.Conclusion. At the hospital stage, the semi-framed epoxy-treated biological prosthesis “T-ara” has a similar clinical and hemodynamic profile with the framed biological prosthesis “UniLine”. The frequency of postoperative heart failure and cardiac arrhythmias is statistically significantly higher in the “UniLine” group (framed bioprostheses).


  • The results of the long-term isolated use of xenopericardial bioprosthesis of the new generation TiAra in the long-term period

    by A.V. Evtushenko, D.I. Lebedev, K.Yu. Shcherbakov, A.V. Shabaldin, V.I. Afanasiev, N.S. Deeva, N.G. Veselovskaya, L.S. Barbarash, 656055 Altai Regional Cardiological Dispensary, Kemerovo Kuzbass Clinical Cardiology Dispensary Named After Academician L.S. Barbarash, et al.

    Результаты изолированного применения ксеноперикардиального биопротеза нового поколения

  • Open Access

    THE LATE DIAGNOSIS OF DANON DISEASE: THE MORPHOLOGICAL CHARACTERISTICS OF LAMP2-CARDIOMYOPATHY (CASE REPORT)

    by Наталья Владимировна Мотина, Nadezhda G. Veselovskaya, Gennady I. Kostyuchenko, Галина Александровна Чумакова, Анна Владимировна Отт, Yuri G. Motin, Геннадий Иванович Костюченко

    Danons disease is a rare and difficult-to-diagnose X-linked hereditary disease caused by a deficiency of lysosome-associated membrane protein 2 or LAMP2. The main clinical symptoms include myocardial damage with the development of hypertrophic LAMP2 cardiomyopathy, skeletal myopathy, and intellectual impairment. The disease is characterized by a rapidly progressive course, which requires dynamic monitoring of patients. The most significant adverse prognostic factor and the main cause of death is the development of cardiomyopathy. But lysosomal accumulation of glycogen in cardiomyocytes often remains unrecognized as the cause of hypertrophic cardiomyopathy. The aim of the study was to conduct a clinical and morphological analysis of a case of late diagnosis of LAMP2 cardiomyopathy in a 44-year-old female patient. We used data from the medical history, the results of intravital laboratory and instrumental studies, qualitative and quantitative morphological studies of endomyocardial biopsy. The results of the study present clinical signs, the results of a morphological study at the light-optical and electronic microscopic levels, and show the features of the structural rearrangement of cardiomyocytes. The formation of multilamellar myelin-like structures under the sarcolemma of cardiomyocytes was found. There were signs of cell damage - significant uneven vacuolization of the sarcoplasm with the detection of fragments of PAS-positive content in individual vacuoles, distortion of cardiomyocytes. There was a disappearance of transverse striation and local violations of the integrity of the sarcolemma. The interstitium was characterized by loose lymphomononuclear infiltration with an admixture of single segmented leukocytes, edema, and small-focal sclerosis, predominantly of the perimuscular type. In the elements of the microvasculature at the light-optical level, signs of endothelial activation were observed. Based on the combination of clinical and anamnestic data, the results of molecular genetic, morphological studies, a metabolic cause of myocardial hypertrophy, previously not clinically recognized, was established with a morphological picture of LAMP2 cardiomyopathy - Danon disease, and an appropriate diagnosis was made. The authors present a rare case of late detection of Danon disease (LAMP2-cardiomyopathy) with the accumulation of autophagocytic material, glycogen in the sarcoplasm of cardiomyocytes, and the formation of osmiophilic myelin-like structures. The presented clinical case clearly demonstrates the practical significance of ultrastructural pathological examination of endomyocardial biopsy to determine the true form of metabolic hypertrophy and assess the degree of morphological myocardial rearrangement.